On October 9, PHARMARON fell 3.26% in regular trading, with a turnover of HK$9.3268 million. The intraday decline was driven by continued market caution over JPMorgan's short-term position volatility in the stock.

Recent disclosures show JPMorgan's long position ratio dropped from 15.31% to 13.90% between September 30 and October 1, then rebounded to 15.30% on October 2 via an off-market transaction acquiring a security interest rather than direct on-exchange buying. This oscillation has weighed on investor sentiment, compounded by weakness across the CRO sector.

PHARMARON operates five segments including laboratory services, chemistry and formulation development, clinical research, and biologics and cell/gene therapy services.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)